Search results for: Multi-Indication Medicines
Filter search results
Asthma
1 February 1990
…same time the importance of prophylactic medicines for asthma has been more fully recognised; this also has made it more desirable to diagnose cases which might previously have been given…
Variations between General Practitioners
1 July 1990
…on variations in GP’s referral rates of patients to hospitals is examined. Second, variations in GP prescriptions for medicines are considered. And third, current policy responses towards these variations are…
The Impact of Behavioural and Biomedical Advance on Health Trends over the Next 25 Years
11 January 1994
…(i.e. new medicines) and other biomedical advances including improved preventative screening, diagnosis and surgical techniques. The earliest study (Brown et al, 1991) considered these issues in the USA, while later…
The Road to Sustainability in the UK and German Biotechnology Industries
1 August 2000
…had an estimated 75 medicines in human clinical trials. Only one UK biotechnology company has successfully launched a new medicine onto the market, however, and none of the top companies,…
The Life Cycle of Pharmaceuticals: A Cross-National Perspective
1 April 2002
…contribution to the methodology of cross-national comparisons for medicines. In this study we use comprehensive data on outpatient sales for all drugs in seven countries (Canada, France, Germany, Italy, Japan,…
Incentives to follow Best Practice in Health Care
1 February 2015
…of health care to follow guidance on best practice, particularly where that guidance requires the use of specific medicines or other health technologies. These incentives include monetary and non-monetary rewards….
Personalised Medicine: is it an Oil-Rush or Oil-Spill?
1 May 2020
…growing importance of personalised medicine. The lighter blue portion of the bars are traditional chemical entities; the darker blue are biologics, and an increasing proportion of those are personalised medicines….
Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?
1 February 2021
…considered when countries decide whether and how much to pay for new medicines and treatments. Our prior work on this topic exposed large gaps between vaccines’ potential broader value and…
Exploring the Financial Sustainability of Gene Therapies
5 January 2021
…by incentivising the development of high-value medicines. A particular concern to payers regarding the concept of value-based pricing is whether or not cost offsets to the health system are taken…